5-hydroxymethyl-2-furfural prolongs survival and inhibits oxidative stress in a mouse model of forebrain ischemia

Bailiu Ya1,2, Lan Zhang1, Li Zhang1, Yali Li1, Lin Li1

1 Department of Pharmacology, Xuanwu Hospital of Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China
2 Department of Physiology, Jining Medical University, Jining 272067, Shandong Province, China

Abstract

In the present study, we hypothesized that 5-hydroxymethyl-2-furfural could attenuate ischemic brain damage by reducing oxidative injury. Thus, mice were subjected to bilateral common carotid artery occlusion to establish a model of permanent forebrain ischemia. The mice were intraperitoneally injected with 5-hydroxymethyl-2-furfural 30 minutes before ischemia or 5 minutes after ischemia. The survival time of mice injected with 5-hydroxymethyl-2-furfural was longer compared with untreated mice. The mice subjected to ischemia for 30 minutes and reperfusion for 5 minutes were intraperitoneally injected with 5-hydroxymethyl-2-furfural 5 minutes prior to reperfusion, which increased superoxide dismutase content and reduced malondialdehyde content, similar to the effects of Edaravone, a hydroxyl radical scavenger used for the treatment of stroke. These findings indicate that intraperitoneal injection of 5-hydroxymethyl-2-furfural can prolong the survival of mice with permanent forebrain ischemia. This outcome may be mediated by its antioxidative effects.

Key Words

5-hydroxymethyl-2-furfural; forebrain ischemia; survival time; oxidative stress; superoxide dismutase; malondialdehyde; mouse

Research Highlights

(1) 5-hydroxymethyl-2-furfural pretreatment and treatment prolonged the survival of mice with permanent forebrain ischemia. In addition, these effects were associated with increased brain superoxide dismutase activity and reduced malondialdehyde content.

(2) The ability of 5-hydroxymethyl-2-furfural to prolong survival may be mediated by these antioxidative effects.

Abbreviations

BCAO, bilateral common carotid artery occlusion; MDA, malondialdehyde; SOD, superoxide dismutase

INTRODUCTION

5-hydroxymethyl-2-furfural (molecular structure shown in Figure 1) is a five carbon-ring aromatic aldehyde[1]. Controversial results about its toxicity have been published over the last few decades. Some studies found that it has toxicity, mutagenicity and carcinogenicity[2-6], and significant adverse effects on the overall metabolism of human blood cells[4], leading to increased activity of hepatic enzymes, altered serum protein profiles and hepatic fatty degeneration[6], as well as the formation of colonic aberrant crypt foci in rats[6]. However, some evidence shows that 5-hydroxymethyl-2-furfural may be...
beneficial to health at an appropriate dose. It is currently in phase I clinical trials for treating sickle cell anemia. At a concentration of 100 μM, 5-hydroxymethyl-2-furfural can inhibit lipid accumulation to influence the differentiation of mouse 3T3-L1 preadipocytes into adipocytes in vitro\[^7\]. 5-hydroxymethyl-2-furfural in the steamed root of *Rehmanniae Radix* may be responsible for the clinical efficacy of the plant, which is used for treating anemia, palpitations and other conditions\[^8\]. Recent studies indicate that 5-hydroxymethyl-2-furfural is an anti-oxidant\[^9\] and protects against hypoxia in vitro\[^10\] and in vivo\[^11\].

Based on these observations, we hypothesized that 5-hydroxymethyl-2-furfural would protect neurons against oxidative stress in ischemic brain injury. To test this hypothesis, we investigated the neuroprotective effect of 5-hydroxymethyl-2-furfural using mice subjected to bilateral common carotid artery occlusion (BCAO; a model of forebrain ischemia) and compared its effects with that of Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolone-5-one), a hydroxyl radical scavenger commonly being used in the management of forebrain ischemic stroke\[^12\].

**RESULTS**

**Quantitative analysis of experimental animals**

In experiment 1, 40 male ICR mice were used. They were equally and randomly assigned to model (normal saline), 4 mg/kg 5-hydroxymethyl-2-furfural, 12 mg/kg 5-hydroxymethyl-2-furfural and Edaravone (10 mg/kg) groups. The treatments were given by intraperitoneal injection 30 minutes before BCAO. All of the mice were included in the final analysis.

In experiment 2, 40 male ICR mice were used. They were equally and randomly assigned to model (normal saline), 4 mg/kg 5-hydroxymethyl-2-furfural, 12 mg/kg 5-hydroxymethyl-2-furfural and Edaravone (10 mg/kg) groups. The treatments were given by intraperitoneal injection 5 minutes after ischemia. One mouse died after anesthesia in the 4 mg/kg 5-hydroxymethyl-2-furfural group. The remaining 39 mice were included in the final analysis.

In experiment 3, 50 male ICR mice were used. They were equally and randomly assigned to sham-surgery (normal saline), model (normal saline), 4 mg/kg 5-hydroxymethyl-2-furfural, 12 mg/kg 5-hydroxymethyl-2-furfural and Edaravone (10 mg/kg) groups. The treatments were given by intraperitoneal injection 5 minutes after reperfusion. All of the mice were included in the final analysis.

**5-hydroxymethyl-2-furfural prolonged survival of mice with permanent forebrain ischemia**

In experiment 1, the Kaplan-Meier survival plots showed that the survival time curves were shifted rightward after 5-hydroxymethyl-2-furfural treatment, indicating that the survival time was longer in the 5-hydroxymethyl-2-furfural groups compared with the model group (Figure 2A). Pretreatment with low and high doses of 5-hydroxymethyl-2-furfural prolonged the survival time by 29% and 33%, respectively, compared with the model group. Edaravone also significantly prolonged survival time (Figure 2B).
3A), indicating a significant increase in survival time (31%) compared with the model group. Edaravone exhibited similar effects as 4 mg/kg 5-hydroxymethyl-2-furfural, not affecting survival time (Figure 3B).

5-hydroxymethyl-2-furfural reduced malondialdehyde (MDA) content in brain tissues of mice with transient forebrain ischemia.

To gain insight into the neuroprotective mechanism underlying the capacity of 5-hydroxymethyl-2-furfural to prolong survival time, we evaluated the ability of the compound to protect against oxidative stress. MDA is a metabolite of lipid peroxidation, which is commonly used to assess the level of oxidative stress in the brain[13]. In experiment 3, transient forebrain ischemia was achieved by performing 30 minutes of BCAO followed by 24 hours of reperfusion. Drugs were given 25 minutes after ischemia (5 minutes before the onset of reperfusion). There was a significant increase in the concentration of MDA in the brain tissue of the model group compared with the sham-surgery group ($P < 0.01$). Treatment with 4 and 12 mg/kg 5-hydroxymethyl-2-furfural significantly reduced MDA contents, by approximately 15% and 21%, respectively, compared with the model group ($P < 0.01$; Figure 4).

5-hydroxymethyl-2-furfural increased superoxide dismutase (SOD) activity in brain tissues of mice with transient forebrain ischemia (Figure 5).
the model group compared with the sham-surgery group ($P < 0.01$). Treatment with 5-hydroxymethyl-2-furfural (12 mg/kg) significantly increased the activity of SOD, by 24%, compared with the model group ($P < 0.01$; Figure 5). Also, Edaravone as a positive control, significantly altered the MDA content and SOD activity under the same experiment conditions.

**DISCUSSION**

The BCAO model has been extensively used to study the impact of ischemic brain injury. It simulates the effects produced by the systemic decrease in blood flow, affects the entire brain, and resembles clinical transient forebrain ischemia in a number of pathological aspects\cite{15-16}. In the present study, the BCAO model was used to evaluate the effect of 5-hydroxymethyl-2-furfural on the survival time of mice. We found that intraperitoneal injection of 5-hydroxymethyl-2-furfural 30 minutes before ischemia or 5 minutes after ischemia significantly prolonged the survival time of mice subjected to BCAO. This finding indicates that 5-hydroxymethyl-2-furfural may not only have a preventive effect against ischemic brain injury, but it may also be beneficial for the treatment of acute stroke. Furthermore, we attempted to identify the mechanisms underlying the ability of 5-hydroxymethyl-2-furfural to prolong survival time. Reactive oxygen species have been shown to contribute to ischemic brain damage. Enhanced generation of reactive oxygen species during brain ischemia may easily overcome anti-oxidant defenses as anti-oxidant enzymes are present in relatively low concentrations in the brain. Reactive oxygen species cause lipid peroxidation, protein oxidation and DNA damage\cite{17-19}. Furthermore, reactive oxygen species can activate diverse downstream signaling pathways, thus regulating the expression of a variety of proinflammatory proteins\cite{20-21}. Such phenomena may become prominent during reperfusion wherein the supply of oxygen and substrates to energy-deprived and metabolically perturbed tissue is restored\cite{22-23}. Antioxidant defenses, including free radical scavengers and antioxidants, are considered the most effective means of attenuating tissue injury induced by ischemia/reperfusion\cite{24-26}. Therefore, the effects of numerous antioxidants on ischemic tissue damage have been evaluated over the last two decades. To investigate the mechanism underlying the protection mediated by 5-hydroxymethyl-2-furfural against ischemic brain injury, lipid peroxidation and antioxidant defenses in the injured brain tissue of mice were measured in the present study. We found that 30 minutes of BCAO ischemia and 24 hours of reperfusion induced an increase in the content of MDA, a metabolite of lipid peroxidation, and a decrease in the activity of SOD, an antioxidant enzyme, in the brain tissue of mice. Intraperitoneal injection of 5-hydroxymethyl-2-furfural 25 minutes after BCAO ischemia (5 minutes before the onset of reperfusion) inhibited lipid peroxidation, as shown by decreased MDA content, and enhanced antioxidant defenses by increasing the activity of SOD, which scavenges free radicals, such as superoxide anions. These results suggest that the neuroprotective effect of 5-hydroxymethyl-2-furfural may be attributable to its antioxidant action. Further study is required to elucidate whether the effects of 5-hydroxymethyl-2-furfural involve other mechanisms. In summary, 5-hydroxymethyl-2-furfural prolongs the survival time of mice subjected to forebrain ischemia induced by BCAO. One of the underlying neuroprotective mechanisms may involve the ability of 5-hydroxymethyl-2-furfural to increase SOD activity and decrease free radical levels.

**MATERIALS AND METHODS**

**Design**

A randomized, controlled, animal experiment.

**Time and setting**

This experiment was performed at the Animal Laboratory of Xuanwu Hospital of Capital Medical University, China from May to December 2009.

**Materials**

**Animals**

A total of 130 male ICR mice of specific pathogen-free grade, aged 3 months, weighing 25–30 g, were purchased from Beijing Vitalriver Experimental Animal Co., Beijing, China (certificate No. SCXK (Jing) 2007-0001), and were housed under a 12-hour light/dark cycle and specific pathogen-free conditions. During the entire experiment, the mice were allowed free access to food and water. All experimental procedures were conducted in accordance with the Provisions and General Recommendations of Chinese Experimental Animal Administration Legislation.

**Drugs**

5-hydroxymethyl-2-furfural was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in sterile saline. 5-hydroxymethyl-2-furfural molecular formula is C6H6O3, with a molecular weight of 126.11. Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolone-5-one) injection was purchased from Nanjing Simcere Pharmaceutical Co., Ltd. (Nanjing, China; No. 070313, certificate No. H20031342).
Methods

Establishment of forebrain ischemia model
Forebrain ischemia model was produced according to a previously described method[27-28]. Briefly, the animals were fasted overnight from food but allowed free access to water. The mice were anaesthetized with 10% chloral hydrate (0.4 mL/kg, intraperitoneal injection) and allowed to breathe spontaneously. During the surgical procedure, the body temperature of the animal was maintained at 37.0 ± 0.5°C with a heating pad. Permanent forebrain ischemia was induced by BCAO. A midline incision was made in the neck, and the bilateral common carotid arteries (BCAs) were carefully exposed and separated from the surrounding connective tissue and nerve fibers, and encircled with a 4/0 silk thread. Then the BCAs were completely occluded using the silk threads. For transient forebrain ischemia, the BCAs were carefully exposed and encircled loosely with 4/0 silk threads to enable later occlusion with non-traumatic artery clips. The BCAs were then occluded using artery clips for 30 minutes. Following the occlusion, the clips were removed to allow complete reperfusion. The sham-surgery mice were subjected to the same procedures except for occlusion of the BCAs. After surgery, the wound was sutured and the animals were placed under heat lamps to maintain body temperature until they fully recovered from anesthesia. The mice were returned to their cage and given free access to water and food. All mice were kept warm using an electric heating blanket before they awoke and were able to move spontaneously.

Interventions
The experimental protocols were as follows: Experiment 1 investigated the effect of pretreatment with 5-hydroxymethyl-2-furfural on the survival time of mice after permanent forebrain ischemia. Mice in the 5-hydroxymethyl-2-furfural and Edaravone groups were intraperitoneally injected with 5-hydroxymethyl-2-furfural (4 or 12 mg/kg) and Edaravone (10 mg/kg), respectively, 25 minutes after ischemia (5 minutes before the onset of reperfusion). The mice in the model and sham-surgery groups received 0.9% normal saline. The mice were sacrificed 24 hours after ischemia/reperfusion. The brain tissues were harvested and homogenized in phosphate buffer to determine MDA levels and SOD activity.

Determination of brain MDA content and SOD activity
Twenty-four hours after forebrain ischemia/reperfusion, the brains were re-anesthetized. Their brains were removed quickly and stored at −80°C until use. For measurements of MDA level and SOD, the brain tissues were homogenized in 0.1 M sodium phosphate buffer (pH 7.4) at a ratio of 1:10 (w/v). Then the homogenate was centrifuged at 3 000 × g at 4°C for 10 minutes. Protein concentrations were determined utilizing Lowry’s method[30], with bovine serum albumin as the standard. MDA level and SOD activity were determined following the kit instructions (SOD Detection Kit and MDA Detection Kit were purchased from Nanjing Jiancheng Bioengineering Institute, Nanjing, China). In brief, MDA content was assessed by measuring levels of thiobarbituric acid reactive substances at 532 nm using a spectrophotometer (WFZ800-3, Beijing Beifen-Ruili Analytical Instrument (Group) Co., Ltd., Beijing, China). The assay for total SOD activity was based on the enzyme’s ability to inhibit the oxidation of oxyamine by O2− produced from the xanthine-xanthine oxidase system. One unit of SOD activity was defined as the capability to reduce the absorbance at 550 nm by 50%. MDA was assayed based on the reaction of MDA with thiobarbituric acid to form a pink chromogen. The results from the thiobarbituric acid reactive substances assay were expressed as MDA equivalents. The measurements were performed according to the detailed procedures provided in the manufacturer’s instructions[31-34].

Statistical analysis
All values were expressed as mean ± SD. The survival time was analyzed with log rank survival analysis of the Kaplan-Meyer survival curves. Statistical significance of differences for SOD activity and MDA levels was calculated using one-way analysis of variance followed by post hoc Fisher protected least significant difference
t-test. A value of $P < 0.05$ was considered statistically significant.

**Acknowledgments:** We thank the staff of Animal Laboratory, Xuanwu Hospital of Capital Medical University, China for animal care.

**Funding:** This project was supported by the National Basic Research Program of China (973 Program), No. 2003CB517104; the National Natural Science Foundation of China, No. 30973513; Beijing Municipal Science and Technology Program, No. D0206001043191; the Natural Science Foundation of Beijing, No.7112061; Beijing Key Foundation of Traditional Chinese Medicine, No. KJTS2011-04; and Beijing Health and Technical Personal of High-Level Plan, No. 2009-3-66.

**Author contributions:** Balliu Ya and Lan Zhang designed the study, conducted experiments, analyzed data and wrote manuscript. Li Zhang and Yali Li provided technical support. Lin Li was in charge of funds, authorized this study and revised this manuscript. All authors read and approved the final manuscript.

**Conflicts of interest:** None declared.

**Ethical approval:** This study received permission from the Animal Care and Research Committee of Xuanwu Hospital of Capital Medical University, China.

**REFERENCES**


(Edited by Wang F, He ML/Su LL/Song LP)